UPB · Upstream Bio
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Market Cap
276M
52 Wk Range
$4.86 - $33.68
Previous Close
$5.04
Open
$5.07
Volume
1,010,578
Day Range
$4.66 - $5.10
Enterprise Value
25.0M
Cash
261.3M
Avg Qtr Burn
-35.62M
Insider Ownership
14.78%
Institutional Own.
92.46%
Qtr Updated
Jun 30th 2026
